Analysis of the key themes driving M&A activity reveals that artificial intelligence accounted for 7 medical devices deals announced in Q3 2022, worth a total value of $3.7m, according to GlobalData’s whitepaper on Artificial Intelligence in Medical Devices – M&A Deal Activity in Q3 2022. The $2.9m acquisition of Pilloxa by iZafe Group was the industry’s largest disclosed deal.
In value terms, artificial intelligence-related deal activity decreased by 82% in Q3 2022 compared with the previous quarter’s total of $20m and fell by 98% as compared to Q3 2021. Related deal volume increased by 133% in Q3 2022 versus the previous quarter and was 22% lower than in Q3 2021.